HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.

AbstractBACKGROUND AND PURPOSE:
Fatigue is a common symptom of Parkinson's disease (PD), often considered by patients as one of the most disabling PD symptoms with significant impact on quality of life. Our aim was to assess the benefits of rasagiline treatment on fatigue in early PD patients.
METHODS:
In this sub-study of ADAGIO (N Engl J Med 2009; 361: 1268), 1105 untreated PD patients were randomized to receive rasagiline 1 mg/day (n = 270) or 2 mg/day (n = 277) or placebo (n = 558) for 36 weeks. The 16-item Parkinson Fatigue Scale (PFS) was assessed at baseline and at week 36/early withdrawal visit. Changes from baseline to last observed visit for each rasagiline group were compared with placebo using ancova.
RESULTS:
Mean baseline PFS score was 2.2 ± 0.9 units. At 36 weeks, patients receiving placebo showed greater progression of symptoms (0.17 units) from baseline in PFS scores compared with the 1 mg/day (0.03 units) and 2 mg/day rasagiline groups (-0.02 units); the difference versus placebo was significant for both rasagiline groups (P < 0.01).
CONCLUSIONS:
Symptoms of fatigue can be detected in patients with early PD and progressively worsen over time. Rasagiline was associated with significantly less progression of fatigue compared with placebo over a 9-month period.
AuthorsF Stocchi,
JournalEuropean journal of neurology (Eur J Neurol) Vol. 21 Issue 2 Pg. 357-60 (Feb 2014) ISSN: 1468-1331 [Electronic] England
PMID23790011 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.
Chemical References
  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression
  • Double-Blind Method
  • Fatigue (complications, drug therapy)
  • Female
  • Humans
  • Indans (therapeutic use)
  • Male
  • Middle Aged
  • Monoamine Oxidase Inhibitors (therapeutic use)
  • Parkinson Disease (complications)
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: